A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trial

Official title: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Status Not yet recruiting

Clinical Trial Summary

This study is a multicenter, open-label, phase II clinical trial to evaluate the safety and efficacy of BL-M07D1+PD-1 monoclonal antibody and BL-M07D1+PD-1 monoclonal antibody+ capecitabine in patients with unresectable locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophageal Neoplasms

• NCT number: NCT06423885
• Study type: Interventional
• Source: Sichuan Baili Pharmaceutical Co., Ltd.
• Contact: Sa Xiao, PHD
• Phone: 15013238943
• Email: xiaosa@baili-pharm.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 2024
• Completion date: June 2026